Intratect

Human normal immunoglobulin, the active ingredient in Intratect, is an immunoglobulin preparation presented as a solution for injection for intravenous use. It provides passive immunity for patients with primary or secondary immunodeficiency and is used in certain immune‑mediated disorders.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Intratect, a pooled human immunoglobulin, is used to replace deficient antibodies and modulate immune activity in several immune‑related conditions.

- Primary immunodeficiency diseases: restores IgG levels to reduce infection risk. - Secondary immunodeficiency: provides passive immunity when antibody production is compromised. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces inflammation and coronary artery complications. - Guillain‑Barré syndrome: shortens disease progression by attenuating autoimmune attack on peripheral nerves.

Intratect may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Headache: mild to moderate headache during or after infusion. - Fever: transient elevation in temperature. - Nausea: mild gastrointestinal upset. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate treatment. - Thromboembolic events: blood clots such as deep vein thrombosis. - Renal dysfunction: acute kidney injury or reduced renal function.

Before administering Intratect, several precautions should be observed. - Pre‑infusion assessment: evaluate patient’s IgG levels and infection history. - Infusion rate: start slowly and monitor vital signs to reduce reaction risk. - Cardiovascular status: monitor patients with heart disease for fluid overload. - Renal function: assess kidney function before administration, especially in high‑risk patients. - Concomitant immunosuppressants: adjust dosing and monitor for increased infection risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other medicines; awareness of major and moderate interactions helps ensure safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine efficacy and increase risk. - High‑dose aspirin or NSAIDs: may increase bleeding risk when combined with immunoglobulin‑induced platelet changes. - Rituximab: may diminish the therapeutic effect of immunoglobulin.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Diuretics: watch for fluid balance changes during infusion. - ACE inhibitors: observe for hypotension during rapid infusion.